Results 41 to 50 of about 5,276 (179)

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

Cancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie, Zixuan Wang, Zhiwen Zeng, Tongyao Xin, Shaofei Yuan, Feiwei Qin, Zhonglin Chen   +6 more
wiley   +1 more source

Interferon‐induced transmembrane (IFITM) proteins at the tumour–immune interface: A four‐axis framework for their context‐dependent roles

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Interferon‐induced transmembrane (IFITM) function in cancer is set by four contextual coordinates, not by family membership. Acute interferon input drives major histocompatibility complex class I (MHC‐I)‐linked immunogenicity; chronic input drives programmed death‐ligand 1 (PD‐L1)‐coupled resistance.
Zhe Liu, Jie Meng, Zengyan Lai, Fuqiu Li, Sha Lv   +4 more
wiley   +1 more source

Criteria for predicting the development of recurrent peripheral nerve sheas tumors

Сибирский онкологический журнал
Peripheral nerve sheaths tumors (PNST) account for about 8 % of all nervous system cancers. The relapse rate ranges from 17.3 to 26.4 %, showing an upward trend. The causes and provoking factors for the development of relapses of PNST have not been fully
A. Yu. Orlov, A. S. Nazarov, A. A. Dolgushin, D. A. Murzaeva, Yu. V. Belyakov, E. A. Oleynik, A. V. Kudziev, Yu. M. Zabrodskaya   +7 more
doaj   +1 more source

Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1 (NF1) Associated Malignant Peripheral Nerve Sheath Tumors (MPNST)

Frontiers in Oncology, 2014
Introduction: Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft tissue sarcomas in which complete surgical resection is the mainstay of therapy.
Jenna eKahn, Jenna eKahn, Andy eGillespie, Maria eTsokos, John eOndos, Eva eDombi, Kevin eCamphausen, Brigitte eWidemann, ARADHANA eKAUSHAL   +8 more
doaj   +1 more source

A Novel Treatment Modality for Malignant Peripheral Nerve Sheath Tumor Using a Dual-Effect Liposome to Combine Photodynamic Therapy and Chemotherapy

Pharmaceutics, 2020
Neurofibromatosis type 1 (NF1) is an inherited neurological disorder. Approximately 5–13% of NF1 patients may develop a malignant peripheral nerve sheath tumor (MPNST), which is a neurofibrosarcoma transformed from the plexiform neurofibroma or ...
Chin-Tin Chen, Po-Chun Peng, Tsuimin Tsai, Hsiung-Fei Chien, Ming-Jen Lee   +4 more
doaj   +1 more source

BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. [PDF]

PLoS ONE, 2014
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive Schwann cell-derived sarcomas and are the leading cause of mortality in patients with neurofibromatosis type 1 (NF1).
Niroop Kaza, Latika Kohli, Christopher D Graham, Barbara J Klocke, Steven L Carroll, Kevin A Roth   +5 more
doaj   +1 more source

DNA Hypomethylation Is Not Cell Intrinsically Toxic to Polycomb Repressive Complex 2 Deficient Malignant Peripheral Nerve Sheath Tumors

Genes, Chromosomes and Cancer, Volume 65, Issue 8, August 2026.
ABSTRACT Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas and the most common cause of disease‐associated death for neurofibromatosis type 1 (NF1) patients. In the context of NF1, MPNSTs develop from benign premalignant precursors and the transition to malignancy is typically accompanied by loss of the polycomb ...
Madilyn R. Stahl, Christopher M. Stehn, Zachary J. Seeman, Christopher Faulk, David A. Largaespada   +4 more
wiley   +1 more source

Intraosseous malignant peripheral nerve sheath tumor of maxilla: A case report with review of the literature

Dental Research Journal, 2014
Malignant peripheral nerve sheath tumor (MPNST), the principle malignancy of peripheral nerve origin, though rare in the general population, occurs with excessive frequency among patients with neurofibromatosis.
Sandhya Tamgadge, Neha Modak, Avinash P Tamgadge, Sudhir Bhalerao   +3 more
doaj   +1 more source

NF1 Leucine Rich Domain‐Derived Extracellular Vesicles Remodel the Glioblastoma Immune Microenvironment via an ADAM17‐Associated Inflammatory Program

Journal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.
NF1‐LRD‐derived EVs suppress glioma cells' invasion and reprogram TAMs through the ADAM17‐TNFα‐ICAM‐1 signaling axis. These EVs reduce migration recruitment, enhance pro‐inflammatory polarization, and modulate key pathways, collectively reshaping the GBM TME. (Created with Biorender.com) ABSTRACT Extracellular vesicles (EVs) are increasingly recognized
Yuganthini Vijayanathan, Jacqueline YT Yeo, Janice HY Tan, Fikri Bin Mohamed, Bernett Lee, Tatsuya Kozaki, Nurashikin Abdul Halim, Rachel LY Ho, Hai Tao Tu, Zhi Wei Zhang, Jann N. Sarkaria, Li Zeng, Florent Ginhoux, Ivy AW Ho   +13 more
wiley   +1 more source

Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth

Journal of Experimental & Clinical Cancer Research, 2019
Background Malignant peripheral nerve sheath tumours (MPNSTs) are sarcomas of Schwann cell lineage origin that occur sporadically or in association with the inherited syndrome, neurofibromatosis type 1 (NF1).
Kang Yang, Wei Guo, Tingting Ren, Yi Huang, Yu Han, Hongliang Zhang, Jie Zhang   +6 more
doaj   +1 more source